MX2022003969A - Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas. - Google Patents

Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.

Info

Publication number
MX2022003969A
MX2022003969A MX2022003969A MX2022003969A MX2022003969A MX 2022003969 A MX2022003969 A MX 2022003969A MX 2022003969 A MX2022003969 A MX 2022003969A MX 2022003969 A MX2022003969 A MX 2022003969A MX 2022003969 A MX2022003969 A MX 2022003969A
Authority
MX
Mexico
Prior art keywords
including sodium
compositions including
sodium phenylbutyrate
palatable compositions
disease
Prior art date
Application number
MX2022003969A
Other languages
English (en)
Inventor
Leah E Appel
Joshua R Shockey
D Christopher Schelling
Original Assignee
Acer Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acer Therapeutics Inc filed Critical Acer Therapeutics Inc
Publication of MX2022003969A publication Critical patent/MX2022003969A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas degustables que incluyen fenilbutirato de sodio y a métodos para el tratamiento de errores innatos del metabolismo (por ejemplo, enfermedad de orina con olor a jarabe de arce o trastornos del ciclo de la urea), trastornos neurodegenerativos tales como la enfermedad de Parkinson, atrofia muscular espinal, distonía o miositis por cuerpos de inclusión, con tales composiciones.
MX2022003969A 2016-03-15 2018-09-14 Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas. MX2022003969A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662308614P 2016-03-15 2016-03-15

Publications (1)

Publication Number Publication Date
MX2022003969A true MX2022003969A (es) 2022-04-25

Family

ID=59847918

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011229A MX2018011229A (es) 2016-03-15 2016-10-17 Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.
MX2022003969A MX2022003969A (es) 2016-03-15 2018-09-14 Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018011229A MX2018011229A (es) 2016-03-15 2016-10-17 Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.

Country Status (21)

Country Link
US (5) US20170266115A1 (es)
EP (2) EP4104822A1 (es)
JP (3) JP7136763B2 (es)
KR (1) KR20190008840A (es)
AU (1) AU2016398029B2 (es)
BR (1) BR112018068665B1 (es)
CA (1) CA3017573A1 (es)
DK (1) DK3429559T3 (es)
ES (1) ES2922749T3 (es)
HR (1) HRP20220856T1 (es)
HU (1) HUE059630T2 (es)
IL (2) IL296490A (es)
LT (1) LT3429559T (es)
MX (2) MX2018011229A (es)
PL (1) PL3429559T3 (es)
PT (1) PT3429559T (es)
RS (1) RS63383B1 (es)
SA (1) SA518400020B1 (es)
SG (1) SG11201807979SA (es)
SI (1) SI3429559T1 (es)
WO (1) WO2017160345A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3429559T1 (sl) 2016-03-15 2022-11-30 Acer Therapeutics Inc. Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe
US20230248657A1 (en) * 2020-07-07 2023-08-10 Acer Therapeutics Inc. Methods of administering taste masked phenylbutyrate and compositions therefor
CN113332267A (zh) * 2021-03-31 2021-09-03 中山大学孙逸仙纪念医院 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用
IT202100019613A1 (it) 2021-07-23 2023-01-23 Kolfarma S R L Formulazione farmaceutica o di integratore alimentare contenente alfa-lattoalbumina e acido butirrico o un suo sale
CN216570857U (zh) * 2021-08-11 2022-05-24 Acer治疗公司 改善药物物质适口性的剂型和多个剂型

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
AR034813A1 (es) 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
FR2850275B1 (fr) 2003-01-24 2005-04-08 Scherer Technologies Inc R P Capsules molles a macher contenant une substance active a gout masque
JP2005060310A (ja) 2003-08-13 2005-03-10 Towa Yakuhin Kk 不快な味をマスキングする経口投与用製剤
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US8236349B2 (en) * 2004-04-12 2012-08-07 Bend Research Inc. Taste-masked drugs in rupturing multiparticulates
WO2008148798A2 (en) * 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
ES2332687B1 (es) 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
JP4706785B2 (ja) * 2008-09-30 2011-06-22 アステラス製薬株式会社 経口投与用粒子状医薬組成物
EP2954780A1 (en) * 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
EP2389932A1 (en) * 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
PT2648528T (pt) 2010-12-06 2016-10-25 Degama Berrier Ltd Composição e método para aperfeiçoar a estabilidade e prolongar a vida útil de bactérias probióticas e produtos alimentares das mesmas
WO2012156997A2 (en) * 2011-05-16 2012-11-22 Sun Pharma Advanced Research Company Ltd Multi-particulate pharmaceutical composition
JP2012240917A (ja) 2011-05-16 2012-12-10 Zensei Yakuhin Kogyo Kk 製剤化用微粒子とそれを含む製剤
EP2717708A1 (en) 2011-06-07 2014-04-16 SPAI Group Ltd. Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof
WO2012175714A1 (en) * 2011-06-22 2012-12-27 Gmp-Orphan Phenylbutyrate in rectal form for the treatment of a motor neuron disease or a metabolic disease
MX2014001556A (es) 2011-08-12 2014-03-31 Boehringer Ingelheim Vetmed Composicion farmaceutica de sabor enmascarado.
EP2599477A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-Phenylbutyric acid sustained release formulation
US8993041B2 (en) 2012-10-15 2015-03-31 New Jersey Institute Of Technology Taste masked active pharmaceutical powder compositions and processes for making them
CN103070844A (zh) 2013-01-28 2013-05-01 万平 一种定位速释生物粘附剂及其应用
JP6147711B2 (ja) 2014-05-26 2017-06-14 富士フイルム株式会社 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
SI3429559T1 (sl) 2016-03-15 2022-11-30 Acer Therapeutics Inc. Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe

Also Published As

Publication number Publication date
ES2922749T3 (es) 2022-09-20
SI3429559T1 (sl) 2022-11-30
HUE059630T2 (hu) 2022-11-28
EP4104822A1 (en) 2022-12-21
US20230133629A1 (en) 2023-05-04
IL261777B2 (en) 2023-02-01
PL3429559T3 (pl) 2022-11-07
AU2016398029B2 (en) 2023-03-02
SA518400020B1 (ar) 2022-12-21
EP3429559A4 (en) 2019-11-06
BR112018068665B1 (pt) 2023-12-26
US11154521B2 (en) 2021-10-26
AU2016398029A1 (en) 2018-10-11
CA3017573A1 (en) 2017-09-21
US20210220304A1 (en) 2021-07-22
BR112018068665A2 (pt) 2019-02-05
LT3429559T (lt) 2022-08-10
KR20190008840A (ko) 2019-01-25
IL296490A (en) 2022-11-01
EP3429559A1 (en) 2019-01-23
SG11201807979SA (en) 2018-10-30
MX2018011229A (es) 2019-05-30
US11433041B2 (en) 2022-09-06
US11202767B2 (en) 2021-12-21
IL261777A (en) 2018-10-31
US20210186908A1 (en) 2021-06-24
JP2019509345A (ja) 2019-04-04
JP2024081748A (ja) 2024-06-18
US20200261385A1 (en) 2020-08-20
IL261777B (en) 2022-10-01
JP7136763B2 (ja) 2022-09-13
WO2017160345A1 (en) 2017-09-21
RS63383B1 (sr) 2022-08-31
HRP20220856T1 (hr) 2022-10-14
DK3429559T3 (da) 2022-07-11
US20170266115A1 (en) 2017-09-21
JP2022106927A (ja) 2022-07-20
WO2017160345A8 (en) 2018-02-22
PT3429559T (pt) 2022-07-20
EP3429559B1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
MX2022003969A (es) Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
EP4292650A3 (en) Heterocyclic compounds as immunomodulators
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
ZA201901536B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
MX2022016434A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
BR112020003865A8 (pt) Composições farmacêuticas compreendendo sepiapterina e seus usos
MX2018012207A (es) Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2018012211A (es) Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2018012208A (es) Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
MX2018012538A (es) Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos.
EP3712264A8 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
MX2018002255A (es) Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa.
PH12021551223A1 (en) Decarboxylase inhibitors for treating parkinson`s disease
MX2022000712A (es) Moduladores de nlrp3.
WO2010000089A8 (en) Stat3 and tyk2 as drug targets for neurodegenerative diseases
WO2018013951A9 (en) Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias
EP3626712A3 (en) Liver x receptor (lxr) modulators
MX2021008941A (es) Moduladores gpr35.
WO2018203664A3 (ko) sRAGE를 분비하는 줄기세포를 포함하는 신경질환 또는 심혈관 질환의 예방 또는 치료용 약학 조성물